Successful Phase 3 results for eltrombopag


In a 93-patient Phase 3 clinical trial, Glaxo's (GSK) Promacta/Revolade (eltrombopag) achieves its primary endpoint of a statistically significant improvement in platelet counts in pediatric patients with chronic idiopathic thrombocytopenic purpura (cITP). 39.7% of patients attained a consistent platelet count for 6 - 8 weeks compared to 3.4% in the control group. The safety profile was also consistent for the established profile for eltrombopag.

The potential use of the product in the pediatric setting is a label expansion. Glaxo has not disclosed a timeline for its regulatory submissions.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs